Payment overview · 2025
General Payments
$292.90
13 reported records · 7 companies
Healthcare provider profile · identity verified
Sam Baroudi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VISTA, CA · NPI 1316936933
Verified facts
What the public records show
CMS Open Payments records show Sam Baroudi, MD received $292.90 in general payments during 2025 across 13 reported records.
ABBVIE INC. accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $101.37 | 34.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.00 | 13.3% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $36.98 | 12.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.60 | 10.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.90 | 10.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.60 | 10.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.45 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $292.90 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $39.97 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $39.97 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $39.97 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $36.98 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $36.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.94 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.60 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.60 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.46 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 142 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
142 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 372 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 101 |
| Gabapentin | Gabapentin | 320 | 87 |
| Losartan Potassium | Losartan Potassium | 316 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 308 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 276 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 62 |
| Metformin Hcl | Metformin Hcl | 204 | 55 |
| Alendronate Sodium | Alendronate Sodium | 190 | 59 |
| Lisinopril | Lisinopril | 190 | 59 |
| Eliquis | Apixaban | 186 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 47 |
| Omeprazole | Omeprazole | 164 | 46 |
| Jardiance | Empagliflozin | 162 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 49 |
| Trazodone Hcl | Trazodone Hcl | 153 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 142 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 46 |
| Montelukast Sodium | Montelukast Sodium | 138 | 41 |
| Ipratropium Bromide | Ipratropium Bromide | 131 | 58 |
| Meloxicam | Meloxicam | 126 | 45 |
| Prednisone | Prednisone | 115 | 74 |
| Furosemide | Furosemide | 110 | 39 |
| Famotidine | Famotidine | 108 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 27 |
| Potassium Chloride | Potassium Chloride | 102 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 97 | 18 |
| Finasteride | Finasteride | 87 | 24 |
| Alprazolam | Alprazolam | 86 | 30 |
| Carvedilol | Carvedilol | 81 | 21 |
| Ozempic | Semaglutide | 81 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 15 |
| Memantine Hcl | Memantine Hcl | 68 | 12 |
| Sertraline Hcl | Sertraline Hcl | 67 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 19 |
| Donepezil Hcl | Donepezil Hcl | 65 | 15 |
| Mirtazapine | Mirtazapine | 65 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 18 |
| Lorazepam | Lorazepam | 56 | 21 |
| Bupropion Xl | Bupropion Hcl | 54 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 53 | suppressed |
| Xarelto | Rivaroxaban | 51 | 12 |
| Fentanyl | Fentanyl | 50 | suppressed |
| Repatha Sureclick | Evolocumab | 50 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 16 |
| Fenofibrate | Fenofibrate | 48 | 13 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Allopurinol | Allopurinol | 45 | 13 |
| Azithromycin | Azithromycin | 45 | 39 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 21 |
| Tramadol Hcl | Tramadol Hcl | 44 | 13 |
| Atenolol | Atenolol | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 11 |
| Cefuroxime | Cefuroxime Axetil | 41 | 32 |
| Ketoconazole | Ketoconazole | 41 | 19 |
| Lidocaine | Lidocaine | 41 | 19 |
| Simvastatin | Simvastatin | 40 | 11 |
| Spironolactone | Spironolactone | 38 | 15 |
| Ezetimibe | Ezetimibe | 37 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Nystatin | Nystatin | 33 | 12 |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 29 | 11 |
| Dexamethasone | Dexamethasone | 26 | 20 |
| Lactulose | Lactulose | 26 | 11 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Testosterone | Testosterone | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Dantrolene Sodium | Dantrolene Sodium | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Minoxidil | Minoxidil | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 14 | 13 |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Triazolam | Triazolam | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | 11 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $292.90 · 13 records | ABBVIE INC. | AIRSUPRA, AVYCAZ, DALVANCE, EMBLAVEO, EVENITY, Flexitouch Plus, LEQVIO, Nimbl, OTEZLA, REPATHA, TEFLARO, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error